Zimmer Biomet Shares Drop 7% as Sales Force Overhaul Prompts Cautious Outlook, Unchanged Revenue Guidance
Summary
Zimmer Biomet issued a cautious outlook for 2026, maintaining its full-year organic revenue growth forecast at 1-3% despite beating first-quarter adjusted EPS and revenue estimates and raising its profit forecast. The company cited ongoing disruption from a U.S. sales force overhaul, which caused "modest disruption" and the loss of two large customer accounts, overshadowing the positive Q1 performance. This news follows earlier 8-K filings today reporting Q1 results and the resignation of CFO Suketu Upadhyay, with shares falling approximately 7% in morning trading. The unchanged revenue guidance and operational challenges from the sales force transition are significant concerns for investors, indicating that 2026 will be a period of transition with execution risks tied to innovation and commercial channel investments. The CFO change adds to the leadership uncertainty during this critical period.
At the time of this announcement, ZBH was trading at $85.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $16.5B. The 52-week trading range was $84.59 to $108.29. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.